This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Insulet's Net Loss Widens, But Revenue Improves

Stocks in this article: PODD

Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.

On March 5, 2009, Insulet (PODD - Get Report), a medical device maker, reported that its Q4 FY08 net loss widened, hurt by a restructuring charge and higher expenses. Net loss stood at $28.28 million, or $1.02 per share, compared to a loss of $15.67 million, or $0.59 per share, in Q4 FY07. Net loss was negatively impacted by a restructuring charge of $8.20 million related to the transition of the company's manufacturing activities to China. The most recent consensus estimate was for a loss of $0.64 per share.

Insulet's revenue surged 172.0% to $11.86 million from $4.36 million in the prior year's quarter. The company improved to a gross profit of 10.10% from a gross loss of 53.15% in the prior year's quarter, as revenue outpaced the cost of revenue, which increased 59.6% to $10.66 million from $6.68 million.

During the quarter under review, research and development expenses spiked 11.5% to $3.54 million from $3.17 million. General and administrative costs increased 34.9% to $6.85 million from $5.08 million. Sales and marketing costs surged 82.2% to $10.00 million from $5.49 million in the year-ago quarter. Operating expenses swelled 107.9% to $28.55 million from $13.74 million, due to the expansion of the company's sales organization and infrastructure and a restructuring charge.

PODD recently announced the appointment of Brian Roberts as chief financial officer.

For FY08, net loss widened to $92.79 million, or $3.36 per share, from a loss of $53.54 million, or $3.21 per share, in FY07. Annual revenue soared 169.7% to $36.06 million from $13.37 million a year ago.

Looking forward to 2009, Insulet estimates revenue to be in the range of $55.00 to $65.00 million. The company also expects its operating loss to be in the range of $50.00 to $60.00 million.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs